Drug Profile
Research programme: anti-TNF compounds - Ception Therapeutics
Latest Information Update: 27 May 2010
Price :
$50
*
At a glance
- Originator Ception Therapeutics
- Class Small molecules
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 31 Jan 2007 Preclinical trials in Inflammation in USA (PO)